Search Results - "Hoffman‐Censits, Jean"

Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell‐free DNA results by Pal, Sumanta K., Bajorin, Dean, Dizman, Nazli, Hoffman‐Censits, Jean, Quinn, David I., Petrylak, Daniel P., Galsky, Matthew D., Vaishampayan, Ulka, De Giorgi, Ugo, Gupta, Sumati, Burris, Howard A., Soifer, Harris S., Li, Gary, Wang, Hao, Dambkowski, Carl L., Moran, Susan, Daneshmand, Siamak, Rosenberg, Jonathan E.

“…Background Infigratinib (BGJ398) is a potent and selective fibroblast grown factor receptor 1 to 3 (FGFR1‐3) inhibitor with significant activity in patients…”
Get full text

Comparison of clinicopathological characteristics, gene expression profiles, mutational analysis, and clinical outcomes of pure and mixed small‐cell carcinoma of the bladder by Parimi, Vamsi, Choi, Woonyoung, Feng, Mingxiao, Fong, Megan, Hoffman‐Censits, Jean, Kates, Max, Lombardo, Kara A., Comperat, Eva, McConkey, David J., Hahn, Noah M., Esteves, Rodrigo Salgado, Matoso, Andres

“…Aims Small cell bladder carcinoma (SCBC) is a rare, divergent form of urothelial carcinoma (UC). We aimed to determine whether pure (n = 16) and mixed (SCBC…”
Get full text

Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes by Hoffman-Censits, Jean H., Lombardo, Kara A., Parimi, Vamsi, Kamanda, Sonia, Choi, Woonyoung, Hahn, Noah M., McConkey, David J., McGuire, Bridget M., Bivalacqua, Trinity J., Kates, Max, Matoso, Andres

“…The antibody-drug conjugate enfortumab-vedotin acts by targeting nectin-4, a protein that is nearly ubiquitously expressed in conventional urothelial cancer…”
Get full text

A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration‐Resistant Prostate Cancer Progressing on Abiraterone by Lin, Jianqing, Patel, Sheel A., Sama, Ashwin R., Hoffman‐Censits, Jean H., Kennedy, Brooke, Kilpatrick, Deborah, Ye, Zhong, Yang, Hushan, Mu, Zhaomei, Leiby, Benjamin, Lewis, Nancy, Cristofanilli, Massimo, Kelly, William Kevin

“…Lessons Learned Patients with metastatic castration‐resistant prostate cancer did not tolerate the combination of alisertib with abiraterone and prednisone…”
Get full text

Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer by Börcsök, Judit, Sztupinszki, Zsofia, Bekele, Raie, Gao, Sizhi P, Diossy, Miklos, Samant, Amruta S, Dillon, Kasia M, Tisza, Viktoria, Spisák, Sándor, Rusz, Orsolya, Csabai, Istvan, Pappot, Helle, Frazier, Zoë J, Konieczkowski, David J, Liu, David, Vasani, Naresh, Rodrigues, James A, Solit, David B, Hoffman-Censits, Jean H, Plimack, Elizabeth R, Rosenberg, Jonathan E, Lazaro, Jean-Bernard, Taplin, Mary-Ellen, Iyer, Gopa, Brunak, Søren, Lozsa, Rita, Van Allen, Eliezer M, Szüts, Dávid, Mouw, Kent W, Szallasi, Zoltan

“…Cisplatin-based chemotherapy is a first-line treatment for muscle-invasive and metastatic urothelial cancer. Approximately 10% of bladder urothelial tumors…”
Get full text

Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma by Bedke, Jens, Merseburger, Axel S., Loriot, Yohann, Castellano, Daniel, Choy, Ernest, Duran, Ignacio, Rosenberg, Jonathan E., Petrylak, Daniel P., Dreicer, Robert, Perez-Gracia, Jose L., Hoffman-Censits, Jean H., Van Der Heijden, Michiel S., Pavlova, Julie, Thiebach, Lars, de Ducla, Sabine, Fear, Simon, Powles, Thomas, Sternberg, Cora N.

“…The value of a complete response to immune checkpoint inhibitor treatment for urothelial cancer is well recognised, but less is known about long-term outcomes…”
Get full text

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial by Rosenberg, Jonathan E, Dr, Hoffman-Censits, Jean, MD, Powles, Tom, Prof, van der Heijden, Michiel S, Prof, Balar, Arjun V, MD, Necchi, Andrea, MD, Dawson, Nancy, Prof, O'Donnell, Peter H, MD, Balmanoukian, Ani, MD, Loriot, Yohann, MD, Srinivas, Sandy, MD, Retz, Margitta M, Prof, Grivas, Petros, MD, Joseph, Richard W, MD, Galsky, Matthew D, MD, Fleming, Mark T, MD, Petrylak, Daniel P, Prof, Perez-Gracia, Jose Luis, MD, Burris, Howard A, MD, Castellano, Daniel, MD, Canil, Christina, MD, Bellmunt, Joaquim, MD, Bajorin, Dean, Prof, Nickles, Dorothee, PhD, Bourgon, Richard, PhD, Frampton, Garrett M, PhD, Cui, Na, PhD, Mariathasan, Sanjeev, PhD, Abidoye, Oyewale, MD, Fine, Gregg D, MD, Dreicer, Robert, Prof

“…Summary Background Patients with metastatic urothelial carcinoma have few treatment options after failure of platinum-based chemotherapy. In this trial, we…”
Get full text

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations by Pal, Sumanta K, Rosenberg, Jonathan E, Hoffman-Censits, Jean H, Berger, Raanan, Quinn, David I, Galsky, Matthew D, Wolf, Juergen, Dittrich, Christian, Keam, Bhumsuk, Delord, Jean-Pierre, Schellens, Jan H M, Gravis, Gwenaelle, Medioni, Jacques, Maroto, Pablo, Sriuranpong, Virote, Charoentum, Chaiyut, Burris, Howard A, Grünwald, Viktor, Petrylak, Daniel, Vaishampayan, Ulka, Gez, Eliahu, De Giorgi, Ugo, Lee, Jae-Lyun, Voortman, Jens, Gupta, Sumati, Sharma, Sunil, Mortazavi, Amir, Vaughn, David J, Isaacs, Randi, Parker, Katie, Chen, Xueying, Yu, Kun, Porter, Dale, Graus Porta, Diana, Bajorin, Dean F

“…BGJ398, a potent and selective pan-FGFR antagonist, was prospectively evaluated in patients with metastatic urothelial carcinoma bearing a diverse array of…”
Get more information

Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Is Safe, Effective, and Efficient Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer: Results of a Multicenter Phase II Study With Molecular Correlates of Response and Toxicity by PLIMACK, Elizabeth R, HOFFMAN-CENSITS, Jean H, KUTIKOV, Alexander, DOTAN, Efrat, BRENNAN, Timothy A, PALMA, Norma, DULAIMI, Essel, MEHRAZIN, Reza, BOORJIAN, Stephen A, KELLY, William Kevin, UZZO, Robert G, HUDES, Gary R, VITERBO, Rosalia, TRABULSI, Edouard J, ROSS, Eric A, GREENBERG, Richard E, CHEN, David Y. T, LALLAS, Costas D, WONG, Yu-Ning, JIANQING LIN

“…Neoadjuvant cisplatin-based chemotherapy is standard of care for muscle-invasive bladder cancer (MIBC); however, it is infrequently adopted in practice because…”
Get full text

Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States by Pal, Sumanta Kumar, Hoffman-Censits, Jean, Zheng, Hanzhe, Kaiser, Constanze, Tayama, Darren, Bellmunt, Joaquim

“…Atezolizumab (anti–programmed death-ligand 1) was approved in the USA, Europe, and elsewhere for treatment-naive and platinum-treated locally…”
Get full text

Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer by Liu, David, Abbosh, Philip, Keliher, Daniel, Reardon, Brendan, Miao, Diana, Mouw, Kent, Weiner-Taylor, Amaro, Wankowicz, Stephanie, Han, Garam, Teo, Min Yuen, Cipolla, Catharine, Kim, Jaegil, Iyer, Gopa, Al-Ahmadie, Hikmat, Dulaimi, Essel, Chen, David Y. T., Alpaugh, R. Katherine, Hoffman-Censits, Jean, Garraway, Levi A., Getz, Gad, Carter, Scott L., Bellmunt, Joaquim, Plimack, Elizabeth R., Rosenberg, Jonathan E., Van Allen, Eliezer M.

“…Despite continued widespread use, the genomic effects of cisplatin-based chemotherapy and implications for subsequent treatment are incompletely characterized…”
Get full text

Four versus 3 Cycles of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Implications for Pathological Response and Survival by Patel, Hiten D, Patel, Sunil H, Blanco-Martinez, Enrique, Kuzbel, Jake, Chen, Victor S, Druck, Aleksander, Koehne, Elizabeth L, Patel, Parth M, Doshi, Chirag P, Hahn, Noah M, Hoffman-Censits, Jean H, Berg, Stephanie, Bivalacqua, Trinity J, Kates, Max, Quek, Marcus L

“…The ideal number of neoadjuvant chemotherapy (NAC) cycles for muscle-invasive bladder cancer is uncertain with 3 to 4 representing the standard of care (SOC)…”
Get full text

Enfortumab vedotin-related cutaneous toxicity correlates with overall survival in patients with urothelial cancer: a retrospective experience by Vlachou, Evangelia, Johnson, Burles Avner, McConkey, David, Jing, Yuezhou, Matoso, Andres, Hahn, Noah M, Hoffman-Censits, Jean

“…Enfortumab vedotin (EV) is an antibody drug conjugate approved for advanced urothelial cancer, consisting of a monomethyl auristatin E payload linked to a…”
Get full text

Enfortumab Vedotin–related Cutaneous Toxicity and Radiographic Response in Patients with Urothelial Cancer: A Single-center Experience and Review of the Literature by Vlachou, Evangelia, Matoso, Andres, McConkey, David, Jing, Yuezhou, Johnson, Burles Avner, Hahn, Noah M., Hoffman-Censits, Jean

“…Enfortumab vedotin (EV) is an antibody-drug conjugate approved for the treatment of refractory advanced urothelial cancer. Cutaneous toxicity is well described…”
Get full text

Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer by Miron, Benjamin, Hoffman-Censits, Jean H., Anari, Fern, O’Neill, John, Geynisman, Daniel M., Zibelman, Matthew R., Kutikov, Alexander, Viterbo, Rosalia, Greenberg, Richard E., Chen, David, Lallas, Costas D., Trabulsi, Edouard J., Alpaugh, R. Katherine, Dulaimi, Essel, Golemis, Erica A., Uzzo, Robert, Ross, Eric A., Plimack, Elizabeth R.

“…Cisplatin-based neoadjuvant chemotherapy (NAC) has demonstrated an overall survival (OS) benefit in muscle-invasive bladder cancer (MIBC). However, only a…”
Get full text

Phase I Trial of Weekly Cabazitaxel with Concurrent Intensity Modulated Radiation and Androgen Deprivation Therapy for the Treatment of High-Risk Prostate Cancer by Lin, Jianqing, Den, Robert B., Greenspan, Jacob, Showalter, Timothy N., Hoffman-Censits, Jean H., Lallas, Costas D., Trabulsi, Edouard J., Gomella, Leonard G., Hurwitz, Mark D., Leiby, Benjamin, Dicker, Adam P., Kelly, W. Kevin

“…Cabazitaxel has been demonstrated to improve the overall survival for men with metastatic castrate-resistant prostate cancer. The purpose of this study was to…”
Get full text

Site of metastatic recurrence impacts prognosis in patients with high-grade upper tract urothelial carcinoma by Cheaib, Joseph G., Claus, Lauren E., Patel, Hiten D., Kates, Max R., Matoso, Andres, Hahn, Noah M., Bivalacqua, Trinity J., Hoffman-Censits, Jean H., Pierorazio, Phillip M.

“…•Twenty-five percent of patients with high-grade upper tract urothelial cancer recur systemically.•Lymphovascular invasion is a strong predictor of metastatic…”
Get full text

Atezolizumab in patients with renal insufficiency and mixed variant histology: analyses from an expanded access program in platinum-treated locally advanced or metastatic urothelial carcinoma by Hoffman-Censits, Jean, Pal, Sumanta, Kaiser, Constanze, Ding, Beiying, Bellmunt, Joaquim

“…BackgroundAtezolizumab is a treatment for locally advanced/metastatic urothelial carcinoma (mUC). However, its use in patients with renal insufficiency or UC…”
Get full text

Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations by Doroshow, Deborah B, O'Donnell, Peter H, Hoffman-Censits, Jean H, Gupta, Sumati V, Vaishampayan, Ulka, Heath, Elisabeth I, Garcia, Philip, Zhao, Qianqian, Yu, Menggang, Milowsky, Matthew I, Galsky, Matthew D

“…Poly (ADP-ribose) polymerase (PARP) inhibitors have demonstrated clinical benefit for patients with solid tumors bearing germline or somatic alterations in DNA…”
Get more information

Development and evaluation of a bladder Cancer specific survivorship care plan by patients and clinical care providers: a multi-methods approach by Lee, Cheryl T, Mohamed, Nihal E, Pisipati, Sailaja, Shah, Qainat N, Agarwal, Piyush K, Downs, Tracy M, Droller, Michael, Gilbert, Scott M, Goltz, Heather H, Hall, Simon J, Hendawi, Mohamed, Hoffman-Censits, Jean, O'Donnell, Michael, Kaag, Matthew, Karsh, Lawrence I, Kassouf, Wassim, Quale, Diane Z, Sagalowsky, Arthur, Steinberg, Gary D, Latini, David M

“…In spite of the mixed evidence for their impact, survivorship Care Plans (SCPs) are recommended to enhance quality of care for cancer survivors. Data on the…”
Get full text